Data shows these compounds have an anti-proliferative effect against CR PCa cells with the ability to simultaneously inhibit AR and PI3K/Akt/mTOR signaling pathways, making them promising therapeutic agents [18]. The gene discussed is AKT1; the disease is posterior cortical atrophy.